Overview of the role of liquid biopsy in cancer management
With the emergence of novel targeted therapeutic options in early-stage and advanced-stage malignancies, researchers have shifted their focus on developing personalized treatment plans through molecular profiling. Circulating tumor DNA (ctDNA) is a cell-free DNA (ctDNA) fragment, originating from tu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-08-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523323000888 |
| _version_ | 1797802848604389376 |
|---|---|
| author | Tarek Assi Rita Khoury Rebecca Ibrahim Maria Baz Tony Ibrahim Axel LE Cesne |
| author_facet | Tarek Assi Rita Khoury Rebecca Ibrahim Maria Baz Tony Ibrahim Axel LE Cesne |
| author_sort | Tarek Assi |
| collection | DOAJ |
| description | With the emergence of novel targeted therapeutic options in early-stage and advanced-stage malignancies, researchers have shifted their focus on developing personalized treatment plans through molecular profiling. Circulating tumor DNA (ctDNA) is a cell-free DNA (ctDNA) fragment, originating from tumor cells, and circulating in the bloodstream as well as biological fluids. Over the past decade, many techniques were developed for liquid biopsies through next-generation sequencing. This alternative non-invasive biopsy offers several advantages in various types of tumors over traditional tissue biopsy. The process of liquid biopsy is considered minimally invasive and therefore easily repeatable when needed, providing a more dynamic analysis of the tumor cells. Moreover, it has an advantage in patients with tumors that are not candidates for tissue sampling. Besides, it offers a deeper understanding of tumor burden as well as treatment response, thereby enhancing the detection of minimal residual disease and therapeutic guidance for personalized medicine. Despite its many advantages, ctDNA and liquid biopsy do have some limitations.This paper discusses the basis of ctDNA and the current data available on the subject, as well as its clinical utility. We also reflect on the limitations of using ctDNA in addition to its future perspectives in clinical oncology and precision medicine. |
| first_indexed | 2024-03-13T05:11:58Z |
| format | Article |
| id | doaj.art-5d0096edcc3d4f3382a53487cad38479 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-03-13T05:11:58Z |
| publishDate | 2023-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-5d0096edcc3d4f3382a53487cad384792023-06-16T05:09:18ZengElsevierTranslational Oncology1936-52332023-08-0134101702Overview of the role of liquid biopsy in cancer managementTarek Assi0Rita Khoury1Rebecca Ibrahim2Maria Baz3Tony Ibrahim4Axel LE Cesne5Corresponding author.; Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceWith the emergence of novel targeted therapeutic options in early-stage and advanced-stage malignancies, researchers have shifted their focus on developing personalized treatment plans through molecular profiling. Circulating tumor DNA (ctDNA) is a cell-free DNA (ctDNA) fragment, originating from tumor cells, and circulating in the bloodstream as well as biological fluids. Over the past decade, many techniques were developed for liquid biopsies through next-generation sequencing. This alternative non-invasive biopsy offers several advantages in various types of tumors over traditional tissue biopsy. The process of liquid biopsy is considered minimally invasive and therefore easily repeatable when needed, providing a more dynamic analysis of the tumor cells. Moreover, it has an advantage in patients with tumors that are not candidates for tissue sampling. Besides, it offers a deeper understanding of tumor burden as well as treatment response, thereby enhancing the detection of minimal residual disease and therapeutic guidance for personalized medicine. Despite its many advantages, ctDNA and liquid biopsy do have some limitations.This paper discusses the basis of ctDNA and the current data available on the subject, as well as its clinical utility. We also reflect on the limitations of using ctDNA in addition to its future perspectives in clinical oncology and precision medicine.http://www.sciencedirect.com/science/article/pii/S1936523323000888DNACirculating tumor cellsCancerMolecular profiling |
| spellingShingle | Tarek Assi Rita Khoury Rebecca Ibrahim Maria Baz Tony Ibrahim Axel LE Cesne Overview of the role of liquid biopsy in cancer management Translational Oncology DNA Circulating tumor cells Cancer Molecular profiling |
| title | Overview of the role of liquid biopsy in cancer management |
| title_full | Overview of the role of liquid biopsy in cancer management |
| title_fullStr | Overview of the role of liquid biopsy in cancer management |
| title_full_unstemmed | Overview of the role of liquid biopsy in cancer management |
| title_short | Overview of the role of liquid biopsy in cancer management |
| title_sort | overview of the role of liquid biopsy in cancer management |
| topic | DNA Circulating tumor cells Cancer Molecular profiling |
| url | http://www.sciencedirect.com/science/article/pii/S1936523323000888 |
| work_keys_str_mv | AT tarekassi overviewoftheroleofliquidbiopsyincancermanagement AT ritakhoury overviewoftheroleofliquidbiopsyincancermanagement AT rebeccaibrahim overviewoftheroleofliquidbiopsyincancermanagement AT mariabaz overviewoftheroleofliquidbiopsyincancermanagement AT tonyibrahim overviewoftheroleofliquidbiopsyincancermanagement AT axellecesne overviewoftheroleofliquidbiopsyincancermanagement |